In 1980 we published the first paper (1) showing that the relaxation of the smooth muscle of isolated arteries induced by acetylcholine (ACh) and other muscarinic agonists is strictly dependent on the presence of endothelial cells, and that the relaxation is mediated by a factor released from these cells on stimulation of their muscarinic receptors. The factor which was not identified chemically appeared to be very labile. By 1982, a number of vasodilators in addition to muscarinic agonists had been shown to produce relaxation of isolated arteries by an endothelium-dependent mechanism. Among these were the calcium ionophore A23187, ATP and ADP, substance P, and bradykinin [in the case of canine and human arteries (2, 3)]. Also, by 1982 a number of agents had been found which inhibited endothelium-dependent relaxation (4). Results with these inhibitors suggested that the endothelium-derived relaxing factor (EDRF) released by various arteries was the same substance. Among these substances are some neurotransmitters, hormones, autacoids, fatty acids and thrombin. It should be emphasized, however, that unlike ACh, A23187, ATP and ADP, and substance P, a number of these substances are selective for species (e.g., histamine for rat and guinea pig but not rabbit; and bradykinin for dog, pig and human but not rabbit and cat), and some are selective for specific arteries in a single species (e.g., vasopressin for cerebral but not femoral arteries in the dog). Some agents have also been demonstrated to produce endothelium-dependent dilation of large conduit arteries in vivo (6). In addition to stimulation of release of DERF by various substances, including many endogenous vasodilators, a basal (spontaneous) release of EDRF from endothelium has been demonstrated in some isolated arteries (7, 8, 9) , and a stimulation of release by increase in flow rate of perfusion fluid (physiological saline or blood) over the endothelium has also been demonstrated both in vitro and in vivo for some large arteries (10, 11). The evidence that agents that relax (dilate) large arteries by release of EDRF also dilate resistance vessels (arterioles) by a similar mechanism is still incomplete, but results so far favor the proposition that at least a large part of the dilation of such vessels by ACh is endothelium-dependent (12). In veins, endothelium-dependent relaxation to agents like ACh, ATP and A23187 is generally much less than in arteries (13).
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Our early speculation (14) that EDRF stimulates the formation of cyclic GMP in the vascular smooth muscle has been proven correct in a number of laboratories (15, 16, 17, 18, 19) . The increase in cyclic GMP precedes the relaxation, indicating a causal role for cyclic GMP.
Previous to studies on DERF, it was known that smooth muscle relaxation by nitrovasodilators (such as glyceryl trinitrate, nitroprusside and nitric oxide) is associated with stimulation of guanylate cyclase and a rise in cyclic GMP (20, 21) . It has been proposed that the relaxation is mediated through cyclic GMP-dependent protein phosphorylation and dephosphorylation of the myosin light chain (22) . Recently there have been two reports on direct activation of guanylate cyclase by EDRF (23, 24) . A few years ago we found that hemoglobin (Hb) (and also myoglobin, but not methemoglobin or metmyoglobin) is a very potent, rapid-acting reversible, selective inhibitor of endothelium-dependent relaxation in preparations of rabbit aorta and other isolated arteries (17, 25, 26, 8, 9, 27, 28) . Inhibition of the increase in cyclic GMP correlated extremely well with the inhibition of relaxation by Hb (8, 27) . The proposal was made that Hb has a very high affinity certain inhibitors (1, 4, 14) , was abandoned when new findings (e.g., production of endotheliumdependent relaxation by saturated as well as unsaturated fatty acids) did not support it (17, 25) .
On the other hand, the proposal that an increase in intracellular Ca++ is an early step in activating the reactions leading to the production and release of EDRF (14) has been supported by work of others (39, 40) .
For more direct studies of the properties of EDRF, perfusion cascade procedures have been developed in which endothelial cells are "upstream" in the perfusion (or superfusion) and an endothelium-denuded arterial preparation, whose contractile state is monitored, is "downstream" to bioassay EDRF in the perfusion fluid. The first successful prodedure of this type (7) used a perfused intact rabbit aorta upstream and a segment of rabbit coronary artery for bioassay.
In our laboratory, we have used perfused rabbit aorta upstream and an endotheliumfree aortic ring downstream (29) . Some laboratories have used superfused cultured endothelial cells (from bovine and porcine aorta) on microcarrier beads in a column as the source of EDRF (30, 31, 32) . With the perfusion cascade systems, it is possible to show whether inhibitors of endothelium-dependent relaxation act on the endothelial cells, on the smooth muscle cells, or on EDRF itself. Fox example, it was shown that certain reducing agents such as phenidone inhibit by acting on EDRF itself (7). In our laboratory, we showed that Hb inhibits by reacting directly with EDRF (31).
In perfusion cascade systems during stimulation of release of EDRF, decreases in relaxation response of the bioassay preraration with increases in transit time of the perfusion fluid have permitted estimations of the half-life (t1/2) of EDRF. Although earlier studies gave t1/2 values around 6 sec (7, 32, 35), considerably longer (e.g., about 25 to 50 sec) and shorter values (e.g., 4 sec or less) have been reported (3, 4, 33) . Two recent studies help explain these differences (33, 37) . In these studies it was found that superoxide dismutase (SOD) markedly About a year ago we proposed that EDRF is the free radical nitric oxide (NO) (41) . The initial evidence for this proposal was obtained in a study of the characteristics of the transient relaxation of rings of rabbit aorta produced by a factor which is generated in NaNO2 solutions on acidification. This factor, which now has been shown to be NO, arises as an intermediate during the decomposition of nitrous acid. We found that NO (either generated in acidified nitrite or as a gas dissolved in an anaerobic solution) is labile (as indicated by transiency of the relaxation), and that its relaxing effect is blocked by Hb, markedly shortened by generators of O 2-and markedly prolonged by SOD (41, 42) . All of these properties are similar to those of EDRF. The threshold for relaxation of rabbit aorta by NO in the presence of SOD is about 0.1 nM. The aim of our present research is directed at answering important fundamental questions about the chemical identity of EDRF, the biochemical mechanism by which it is formed in and released from endothelial cells, the biochemical mechanism by which it causes relaxation of smooth muscle cells, and the possible chemical relationship between EDRF and other relaxing factors of biological origin. In view of findings on the basal release of EDRF, and on stimulation of its release by increases in hemodynamic shear stress, by vasoactive hormones (e.g., vasopressin and cholecytokinin), by neurotransmitters (e.g., acetylcholine, substance P, VIP, ATP), by autacoids that modulate local blood flow (e.g., histamine and bradykinin), and by substances involved in hemostasis (e.g., thrombin, serotonin and ADP), it now appears that local release of EDRF from endothelial cells may have an important physiological role as a mediator of dilating activity in certain vessels and vascular beds under specific conditions. Further research is required to determine whether decreased capacity for EDRF elaboration due to loss or dysfunction of endothelial cells may play a role in pathological vascular events associated with atherosclerosis, thrombogenesis and vasospasm.
